Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCLBKK:HL +1.75%76 PS Ratio is 0.69 as of Jul. 27, 2026, which is 60% below its 10-year median of 1.71. GuruFocus rates BKK:HL with a GF Score™ of 76/100 and a GF Value™ of ฿10.92 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 658 Healthcare Providers & Services companies, Healthlead PCL ranks better than 72.64% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Healthlead PCL's share price is ฿5.80.
Healthlead PCL's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ฿8.42. Hence, Healthlead PCL's PS Ratio for today is 0.69.
Good Sign:
Healthlead PCL stock PS Ratio (=0.69) is close to 5-year low of 0.65.
The historical rank and industry rank for Healthlead PCL's PS Ratio or its related term are showing as below:
BKK:HL'
s PS Ratio Range Over the Past 10 Years
Min: 0.65 Med: 1.71 Max: 6.21
Current: 0.69
During the past 7 years, Healthlead PCL's highest PS Ratio was 6.21. The lowest was 0.65. And the median was 1.71.
BKK:HL's PS Ratio is ranked better than 72.64% of 658
companies
in the Healthcare Providers & Services industry
Industry Median: 1.465
vs BKK:HL: 0.69
During the past 12 months, the average Revenue per Share Growth Rate of Healthlead PCL was 10.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 13.80% per year.
During the past 7 years, Healthlead PCL's highest 3-Year average Revenue per Share Growth Rate was 18.80% per year. The lowest was 7.80% per year. And the median was 14.75% per year.
Back to Basics: PS Ratio
Healthlead PCL (BKK:HL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Healthlead PCL PS Ratio Related Terms
Healthlead PCL PS Ratio Historical Data
* Premium members only.
The historical data trend for Healthlead PCL's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Healthlead PCL's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's PS Ratio distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Healthlead PCL's Share Price of today is ฿5.80. Healthlead PCL's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿8.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Healthlead PCL (BKK:HL) has a PS Ratio of 0.69 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Healthlead PCL and its competitors. This is 60% below median its historical median of 1.71. Over the past decade, Healthlead PCL's PS Ratio has ranged from 0.65 to 6.21. According to the industry distribution chart, Healthlead PCL ranks #180 out of 658 companies in the Healthcare Providers & Services industry, placing it in the top 27.4%.
Is Healthlead PCL's PS Ratio too high?
Healthlead PCL's current PS Ratio of 0.69 is 60% below median its 10-year median of 1.71. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 6.21. The Healthcare Providers & Services industry median PS Ratio is 1.47. Healthlead PCL's value of 0.69 is 52.9% below this industry median. Based on the distribution chart, Healthlead PCL ranks #180 out of 658 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Healthlead PCL has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's PS Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #180 out of 658 companies for PS Ratio. This puts Healthlead PCL in the upper half of its industry. The industry median PS Ratio is 1.47. Healthlead PCL's value of 0.69 is 52.9% below this benchmark. Historically, Healthlead PCL's own PS Ratio has ranged from 0.65 to 6.21 over the past decade. While the company's 10-year median is 1.71 vs. the industry median of 1.47, Healthlead PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.47, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthlead PCL's current PS Ratio of 0.69 is 52.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Healthlead PCL and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current PS Ratio is 0.69, which is 60% below median its own 10-year median of 1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.92, compared to a current price of ฿5.80 — trading 46.9% below its estimated fair value. The current PS Ratio is 0.69, which is 60% below median its 10-year median of 1.71 and 52.9% below the Healthcare Providers & Services industry median of 1.47. Healthlead PCL's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current PS Ratio is 0.69 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿5.80 is trading 46.9% below its estimated GF Value™ of ฿10.92.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
PS Ratio: 0.69 (60% below median its 10-year median of 1.71)
GF Value™: ฿10.92 vs. price of ฿5.80 (46.9% below fair value)
Industry Position: 52.9% below the Healthcare Providers & Services median (#180 of 658)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
76GF Score
Get the complete analysis for BKK:HL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
